Table 2.
Results of subgroup analysis
Subgroup | No of studies | Random-effects model
|
Fixed-effects model
|
Heterogeneity
|
|||
---|---|---|---|---|---|---|---|
HR (95% CI) | P-value | HR (95% CI) | P-value | I2 (%) | P-value | ||
Predominant treatment | |||||||
Surgery | 10 | 1.46 (1.26–1.68) | <0.01 | 1.41 (1.26–1.58) | <0.01 | 27.3 | 0.19 |
Chemotherapy | 3 | 1.78 (1.48–2.13) | <0.01 | 1.78 (1.48–2.13) | <0.01 | 0.0 | 0.70 |
Country | |||||||
Japan | 6 | 1.66 (1.29–2.14) | <0.01 | 1.57 (1.28–1.93) | <0.01 | 23.4 | 0.26 |
Other | 7 | 1.51 (1.30–1.77) | <0.01 | 1.49 (1.33–1.66) | <0.01 | 44.5 | 0.09 |
Sample size | |||||||
<300 | 6 | 1.73 (1.35–2.20) | <0.01 | 1.60 (1.34–1.92) | <0.01 | 28.7 | 0.22 |
≥300 | 7 | 1.48 (1.27–1.73) | <0.01 | 1.47 (1.31–1.65) | <0.01 | 39.5 | 0.13 |
NOS score | |||||||
<7 | 5 | 1.65 (1.41–1.92) | <0.01 | 1.64 (1.42–1.88) | <0.01 | 16.2 | 0.31 |
≥7 | 8 | 1.46 (1.22–1.74) | <0.01 | 1.39 (1.22–1.59) | <0.01 | 30.6 | 0.18 |
Abbreviations: HR, hazard ratio; CI, confidence interval; NOS, Newcastle–Ottawa Quality Assessment Scale.